FibroGen falls on U.S. safety data for roxadustat

FibroGen lost $9.28 (20%) to $36.39 on Friday after pooled safety analyses of Phase III data of anemia therapy roxadustat raised concerns for investors ahead of planned regulatory filings this fall.

Omega Funds’ Otello Stampacchia told BioCentury that the company's presentation of the data to treat anemia associated with chronic kidney disease lacked clarity. “It is quite likely that this was the result of some negotiation between themselves, AZ and possibly the FDA but it was definitely very confusing.”...